Vinorelbine Plus Cisplatin Or Vinorelbine Plus Lobaplatin In The Treatment Of Advanced Breast Cancer Failure To Anthracyclines And Taxanes

Objective: To evaluate the results of combination chemotherapy withvinorelbine plus cisplatin (NP) or vinorelbine plus lobaplatin (NL) in thetreatment of patients with advanced breast cancer failure to anthracyclines andtaxanes, and to provide more evidence sources to the treatment for patients withadvanced breast cancer failure to anthracyclines and taxanes.Methods：From January2008to December2011, in Cancer Hospital,Guangxi Medical University,82patients with advanced breast cancer failure toanthracyclines and taxanes were enrolled in this study. In NP group, fifty-fourpatients received vinorelbine25mg/m2on day1and8, with cisplatin30mg/m2on day l to3, and in NL group, twenty-eight patients received vinorelbine25mg/m2day1and8, lobaplatin30mg/m2on day l. The treatments wererepeated every three weeks and the therapeutic effects were observed two cycleslater. The efficacy, time to progression (TTP) and adverse events wereobservated. Result: The overall response rate （RR）was71.4％(20/28) in NL, whichWas higher than48.1％(26/54) in NP (P<0.05). The clinical benefit rate(CBR)was89.3%（25/28）in NL, which Was higher than87%（47/54） in NPwith nosignificant difference (P>0.05).The median time to progression Was912days in NP, which Was higher than720days in NL with nosignificant difference(P>0.05). The single factor analysis shows that age，receptor and metastasis notcause between different efficacy ignificantly. The main toxieities weremyelosuppression, gastrointestinal tract reaction． The rate of vomiting,ototoxicity of group NP were higher (P<0.05). But the rate of decrease ofplatelet of group NL were higher (P<0.05).Conclusion: For the patients with advanced breast cancer failure toanthracyclines and taxanes, vinorelbine plus lobaplatin is very active andtolerable as vinorelbine plus cisplatin. The regimem should consider as areasonable option in the patients with advanced breast cancer failure toanthracyclines and taxanes.